Ind-Swift Laboratories Limited has submitted its mandatory compliance certificate under SEBI regulations for the quarter ended 31st March, 2026. The pharmaceutical company filed the certificate with BSE Limited and National Stock Exchange of India Limited on 3rd April, 2026, fulfilling its regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The compliance certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Pardeep Verma, VP-Corporate Affairs and Company Secretary of Ind-Swift Laboratories Limited, submitted the certificate to both stock exchanges where the company's shares are listed.

Certificate Confirmation

Alankit Assignments Limited, serving as the Registrar and Share Transfer Agent for Ind-Swift Laboratories Limited, issued the compliance certificate dated 1st April, 2026. The certificate was signed by Kamal Garg, General Manager at Alankit Assignments Limited.

The compliance certificate confirms two critical aspects of the dematerialization process:

• The securities comprised in the certificates have been listed on the Stock Exchanges
• The certificates after due verification have been mutilated and cancelled, with the name of depository substituted in records as registered owner

Company Information

Ind-Swift Laboratories Limited operates from its registered office located at SCO 850, Shivalik Enclave, NAC Manimajra, Sector 13, Chandigarh. The company maintains two manufacturing facilities - Unit I at NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab, and Unit II at Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir.

Regulatory Framework

The filing represents compliance with SEBI's mandatory requirements for companies whose shares are held in dematerialized form. Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 mandates that registrar and transfer agents provide quarterly certificates confirming proper handling of physical share certificates received for dematerialization.

This quarterly compliance filing demonstrates Ind-Swift Laboratories Limited's adherence to regulatory requirements and proper maintenance of shareholder records through its appointed registrar and transfer agent.

Ind-Swift Laboratories Limited has completed the allotment of equity shares under its Employee Incentive Scheme 2014, marking another step in its employee benefit initiatives. The pharmaceutical company informed stock exchanges about this corporate action through a regulatory filing dated March 31, 2026.

Share Allotment Details

The Compensation Committee of Ind-Swift Laboratories approved the allotment of 1,25,000 equity shares to eligible employees during its meeting held on March 31, 2026. The allotment was conducted under the Employee Incentive Scheme 2014, which was originally filed with stock exchanges on June 2, 2015.

Updated Share Capital Structure

Following the allotment, the company's share capital structure has been revised. The paid-up equity share capital now stands at ₹86,83,65,580, representing an increase from the previous capital base.

Regulatory Compliance

The allotment was conducted in compliance with SEBI regulations, specifically under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided detailed disclosures as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Key regulatory aspects include:

• The shares are identical in all respects to existing equity shares
• No lock-in period applies to the allotted shares
• The shares are issued in demat form with ISIN number INE915B01019
• No listing fees are payable for this allotment

Stock Exchange Listing

Ind-Swift Laboratories' equity shares are listed on both BSE Limited and National Stock Exchange of India Limited. The company trades under the scrip code 532305 on BSE and symbol INDSWFTLAB on NSE. The newly allotted shares will be traded on both exchanges without any restrictions.

The Employee Incentive Scheme 2014 demonstrates the company's commitment to employee participation in its growth story through equity-based compensation. The scheme allows eligible employees to acquire company shares at predetermined prices, aligning their interests with long-term shareholder value creation.